CD33 and acute myeloid leukemia: Later, development of antibody humanization techniques and conjugation to more potent drugs contributed to the approval in 2000 by the FDA of the first ADC (Gemtuzumab ozogamicin), raised against the CD33 molecule for acute myeloid leukemia (AML) treatment.